Fresh analysis suggests that patients who discontinue popular weight-loss injections like Mounjaro or Wegovy can put back on lost weight much more quickly than those who halt conventional lifestyle programs.
Published data in a leading health publication demonstrates that while obese individuals can lose a large proportion of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Users buying these medications must be cognizant of the risk of rapid rebound weight gain when the treatment concludes," warns lead investigator Dr. Susan Jebb.
That rate of recovery suggests a reversion to starting mass in about a year and a half.
Weighing Approaches
The research, which examined 37 of studies involving thousands of participants, compared the effects of GLP-1 agonists with older methods.
Scientists point out that people who shed pounds through diet and exercise typically see a more gradual creep back—around 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Experts propose the way of the drugs explains the heightened regain.
These medications copy a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of GLP-1 levels far above than normal may cause the body to generate a reduced amount of its endogenous hormone, and may also reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' means hunger is uncontrolled, making binge eating a significant risk."
An Ongoing Condition?
Medical guidelines advise the jabs for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Professionals argue that, considering the significant potential of relapse, the therapy should be considered life-long.
This opinion is reinforced by drug manufacturers, who state that the results "underscore the long-term character of obesity," similar to managing diseases like hypertension.
Patient Experiences
Individuals who have come off the jabs explain a powerful return of cravings.
"It felt as if a trigger flipping and you're instantly extremely hungry," described a patient.
This challenge is exacerbated if individuals have not developed lasting lifestyle or habit modifications during therapy.
Widespread Adoption
Figures show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow.
- Use is more common among women than men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
In conclusion, experts emphasize that while the jabs are potent tools for weight loss, they are not a standalone solution and long-term success likely depends on ongoing behavioural management.
